Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

“…<p><b>(A)</b> Manhattan plot of minJSW decrease at 24 months. The Manhattan plots show the -log10(P) values of all ~ 1,5 million SNPs against their position. …”

Analysis of Significantly Different ARGs and Resistance Mechanisms. by Xu Jia (187142)

MiR-129-5p levels were decreased in mouse depression models. by Qiaozhen Qin (13159201)

Subjects:

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)

RTL8 incorporates into PEG10 VLPs and decreases the efficiency of release. by Will Campodonico (20485651)

NgR1 KO mice exhibited an increase in excitatory synapses and a decrease in inhibitory synapses, indicating an imbalance of synaptic transmission. by Jinwei Zhang (462455)

“…The inhibitory synaptic density of NgR1 mice showed a significant decrease when compared to WT mice (***P <  0.001). …”

DHE reports decreased cholesterol uptake by ∆<i>mceG</i> Mtb. by Yue Chen (73753)

Loss of Vps34 is associated with decreased eTreg survival but intact activation. by Erienne G. Norton (9612079)

Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

IRE1 depletion decreases heterochromatin, DNA and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

IRE1 depletion decreases heterochromatin, DNA, and H3K9me3 methylation, and UHRF1. by Iratxe Zuazo-Gaztelu (21071939)

Subjects:

Voxel-based whole-hemisphere analysis shows regional and dose-dependent decrease of microglia. by Francesca Catto (21253435)

“…<p>(A) Each 3-dimensional map of statistically affected voxels (p < 0.05, with the red scale, representing the significance in decrease of microglia, and the cyan scale, representing the increase in microglia; reference atlas is grey) summarizes all the treated and control samples within a cohort (3 samples per group). …”

Brain regions with significantly decreased activations for the Raven task are shown in blue. by Morteza Fattahi (15892028)

Summary of significant treatment × time effect. by Wensheng Xiao (16557866)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”